Amid ongoing investigations and the indictment and guilty plea of former Del. Cheryl D. Glenn (D-Baltimore City), House lawmakers received an update Wednesday from the leaders of the Natalie M. LaPrade Medical Cannabis Commission.
During the briefing before the House Health and Government Operations Committee, Executive Director William Tilburg addressed the series of problems that the commission has faced in the last few months — notably licensure application delays and Glenn’s charges.
Glenn resigned in December ahead of bribery and federal wire fraud charges raised against her for pushing cannabis legislation for personal economic gain. She pleaded guilty during an arraignment held Wednesday afternoon in Baltimore.
Tilburg said that Glenn was passionate about medical marijuana legislation and advocated for the creation of the commission, which was named for her mother. He also described her as a critic who pushed for equity in the program.
In light of “all the stories and the allegations, and the hearing that’s going on momentarily in Baltimore,” Tilburg made clear that lawmakers, including Glenn, had no hand in the following:
- Developing emergency regulations meant to address inequities in the certification process
- The redevelopment of licensure applications
- Evaluating or giving feedback on any applications
Click here to read the rest of the article written by Hannah Gaskill over at Maryland Matters